Kornimate/medical-research-clean huggingface dataset:
expressive writing for covid-19 resilience for parents

Conditions: Parents During COVID-19

Summary: the purpose of this study is to determine the impact of a 4-week, virtually-delivered expressive writing intervention on resilience in a cohort of parents and caregivers currently navigating the covid-19 pandemic during spring \& summer of 2020.

in 2016, the research team piloted a 6-week intervention on expressive writing for resilience in a population of trauma survivors. participants self-identified as having had a recent trauma or significant life upheaval, such as a divorce, major illness, job loss, or the death of a loved one. at 6 weeks, the investigators found that participants experienced significantly improved levels of resilience and lower levels of stress, rumination, and depression. these results added to a growing body of research indicating the potential for expressive writing to be a powerful healing modality for both psychological and physical well-being. the current covid-19 pandemic presents the potential for trauma or significant life upheaval for nearly all members of the community and the world at large. parents of children who are at home face unique challenges during this time. social distancing guidelines, shelter in place protocols, school and business closures, travel restrictions, high levels of job loss, loss of childcare, and the looming threat of illness have disrupted daily routines, family life, and significantly altered life plans for many. parents and caregivers who have unexpectedly lost childcare, are having to adjust to home schooling arrangements, and/or are having to end to heightened emotional needs in their children may experience this time as particularly difficult. resilience is the capacity for individuals to adapt and recover in the face of trauma, adversity, or significant sources of stress. the current collective reality magnifies the need for accessible, low-cost, effective interventions to help people cultivate resilience and other dimensions of psychological well-being. in this study, the investigators seek to further the work the research team began in 2016 with a 4-week, virtually-delivered expressive writing intervention designed to support parents in cultivating personal resilience and emotional wellness during the covid-19 pandemic.

Eligibility criteria:
inclusion criteria: in order to have up to 40 evaluable subjects, we plan to consent up to 45 individuals. potential subjects will be considered eligible if they are parents or primary caregivers of children aged 0-18 who have been home with them during the covid-19 experience. other eligibility criteria include: * able to speak, read, write, and understand english * cognitively able to provide consent * ability to participate in a 4-week intervention delivered via zoom and email
defiances to face covid-19 pandemic in mexico

Conditions: Health Behavior; Risk-Taking; Covid19

Summary: the aim of this study is to identify the risk factors favoring the contagion of covid-19 by studying the quarantine behavior and preventive measures in the mexican population. as a secondary aim, the investigators sought to identify areas that need reinforcement, to help develop strategies for a successful plan to face an upcoming pandemic.


Eligibility criteria:
inclusion criteria: * being mexican or residents of the country * participants over 15 years exclusion criteria: * participants under 15 years of age * participants with incomplete surveys * being a tourist currently staying in the country or being mexican residing in another country

Keywords: health behavior pandemic risk-taking mexico covid-19
use of perioperative antibiotics in endoscopic sinus surgery

Conditions: Chronic Sinus Infection

Summary: the objective of this study is to determine whether the use of postoperative antibiotics following endoscopic sinus surgery (ess) decreases postoperative infection rates. this is a multi-institutional prospective study involving albert einstein college of medicine/montefiore medical center, columbia university medical center, weill cornell medical college, mount sinai health system, and new york university langone medical center. the study design will be a multi-institutional prospective randomized controlled trial with parallel random groups assigned to receive postoperative antibiotics or no postoperative antibiotics. the investigators hypothesize that patients who receive postoperative antibiotics will have lower postoperative infection rates and improved postoperative sinonasal symptoms and nasal endoscopy scores.


Eligibility criteria:
inclusion criteria: * patients with chronic rhinosinusitis (crs) with or without nasal polyposis or allergic fungal rhinosinusitis who present to the otolaryngology clinic who have been deemed suitable for bilateral ess, and are over the age of 18 will be included. exclusion criteria: * patients with sinonasal tumors, allergies or adverse reactions to all of the antibiotics that will be used in this study (amoxicillin-clavulanate, doxycycline, clarithromycin), immunodeficiency, cystic fibrosis, pregnancy, or diabetes with nasal polyposis (inability to receive systemic steroids) will be excluded, as will patients who lack capacity to provide informed consent. patients undergoing active treatment for malignancy will be excluded. patients undergoing unilateral ess or with nonabsorbable packing placed at the time of surgery will be excluded. patients who have been on antibiotics within 2 weeks of the surgery date will be excluded. patients with acute on chronic sinusitis or the presence of purulence at time of surgery will be excluded from the study.

Keywords: endoscopic sinus surgery antibiotics
ercp in idiopathic recurrent acute pancreatitis

Conditions: Recurrent Acute Pancreatitis

Summary: the therapeutic impact of ercp with sphincterotomy in the management of patients with idiopathic recurrent acute pancreatitis (rap) needs further study. the investigators conducted a single center, feasibility, randomized trial to determine 1) the role of pancreatic manometry in predicting future episodes of rap and 2) differences in the efficacy of no, biliary (bes) or pancreatobiliary (dual) endoscopic sphincterotomy (des).

patients with idiopathic rap, defined as ≥2 unexplained (per the treating physician) episodes of acute pancreatitis (based on standard criteria) requiring hospitalization, will be prospectively enrolled. all patients will undergo ercp with manometry, with stratified randomization based on the assessment of pancreatic basal sphincter pressure. if \<40mmhg, the patient will be randomized to sham or biliary sphincterotomy (bes). if ≥40mmhg, the patient will be randomized to bes or pancreatobiliary ("dual") sphincterotomy (des). patients and physicians will not be blinded to the assignment group. patients will be followed for up to 10 years to determine 1) incidence of rap requiring hospitalization (using standard definitions) or 2) interval development of chronic pancreatitis (cp). differences between patients who did and did not develop rap during follow-up will be compared to evaluate for factors associated with ap during follow-up.

Eligibility criteria:
inclusion criteria: * idiopathic recurrent acute pancreatitis, defined as two or more episodes requiring hospitalization * ercp with som planned exclusion criteria: * chronic pancreatitis * pancreas divisum * alternate etiology identified (e.g., cbd stone, ipmn) * inability to perform pancreatic manometry * pregnancy, age \< 18, incarceration * inability to provide informed consent

Keywords: acute pancreatitis ercp sphincterotomy manometry sphincter of oddi dysfunction
study on the tailored intervention strategy of childhood obesity based on monitoring physical activities and dietary behaviors

Conditions: Pediatric Obesity

Summary: the project aims at developing the tailored intervention strategy of childhood obesity based on monitoring physical activities with accelerometer and dietary behaviors using diary. it probably raise the passion of obese children to control weight, form healthy life style, be effective in sustaining weight loss and early prevent adulthood diseases.

the overweight and obese primary school students from 1-5 grades will be recruited according to "body mass index reference for screening overweight and obesity in chinese school-age children". the participants with will be allocated with schools as the unit to four groups: tailored intervention based on monitoring physical activity and dietary behaviors, exercise intervention group based on the happy 10 program, nutrition education intervention group. the three intervention groups received the designed interventions for the duration of 1 year. before and after the intervention, we will carry out a questionnaire survey, a physical measurement, a fitness test, and a metabolic markers detection

Eligibility criteria:
inclusion criteria: * overweight and obese children from grade 1-5 primary schools exclusion criteria: * students with any contraindication or physical diseases (heart, lung, liver, kidney, other vital organs, endocrine diseases and drug side effects et al.) and psychological illnesses that may prevent them from participating in physical activity and eating a normal diet were excluded

Keywords: childhood obesity, intervention, effectiveness, comparison
pioglitazone for lung cancer chemoprevention

Conditions: Lung Cancer; Endobronchial Dysplasia

Summary: this is a chemoprevention trial evaluating the diabetic agent pioglitazone. non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either placebo or pioglitazone and have chest computerized tomography (cat) scans and examinations of their airways with a bronchoscope at the start of the trial and after 6 months on treatment. compensation will be provided to the subject after completing the trial.

this trial evaluates the oral peroxisome proliferator-activated receptor gamma (ppargamma) agonist pioglitazone in a double-blind placebo controlled trial. the high risk current and former smokers qualify based on tobacco exposure, airflow limitation on lung function testing, and sputum cytologic atypia. subjects have a quantitative high resolution thoracic ct scan and a fluorescent bronchoscopy at study entry and after 6 months on drug or placebo. biologic samples are collected at both time points. the primary outcome is endobronchial histology and determining if pioglitazone can retard progression. secondary endpoints related to the ppar gamma signaling pathway will also be analyzed.

Eligibility criteria:
inclusion criteria: * current or former smoker (at least 10 pack years); * one or more of the following: * mild or worse sputum atypia * airflow limitation (fev1/fvc\<70% predicted) * biopsy proven airway dysplasia exclusion criteria: * myocardial infarction (mi) with ejection fraction \< 50%; * severe/unstable angina; * history of coronary or peripheral arterial bypass grafting; * new york heart association (nyha) class iii or iv congestive heart failure; * hypoxemia (less than pox 90 with supplemental oxygen); diabetes type i or ii; severe copd (gold stage iii or iv); clinically significant edema requiring diuretic therapy; * life expectancy \< 6 months; history of bladder cancer * pregnant or breast feeding; inability to give informed consent

Keywords: chemoprevention lung cancer pioglitazone
efficacy and safety of efalizumab in the treatment of moderate-severe hydradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.

the primary objective of this study is to assess the efficacy of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa. the secondary objectives of this study are to assess the ability to re-establish disease control after discontinuation of drug and allowance for relapse of disease, as well as to assess the safety of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa.

Eligibility criteria:
inclusion criteria: * female between 18-65 years of age * has hydradenitis suppurativa (hs) involving at least 1 area of the body with greater than or equal to 12 lesions; onset of disease is 6 months and greater. * failed at least 3 months of standard conventional therapies such as antibiotics and/or systemic retinoids * willing to use contraception unless not of childbearing potential * able to comply with protocol requirements exclusion criteria: * received within 4 weeks prior immunosuppressive medication * received treatment within 3 months prior with systemic retinoids (acitretin or isotretinoin) * received high potency (class i or ii) topical corticoid steroids, topical antibiotics, systemic antibiotics, or topical immunomodulators (tacrolimus or pimecrolimus) within 2 weeks prior to baseline visit * received intralesional injections of corticosteroids within 4 weeks prior * received surgical intervention for the treatment of hs * known history of hiv seropositivity * history of untreated or active tuberculosis * active infection requiring systemic antibiotics within 4 weeks of baseline visit * history of recurrent/chronic infections * history of malignancy within 5 years of baseline visit (except for squamous cell carcinoma or basal cell carcinoma; may enroll if treated and assessed as cured). * pregnant or breastfeeding * immunocompromised due to a medical condition * has any significant laboratory abnormalities * has any medical condition that may interfere with evaluation of the safety and efficacy of efalizumab * received efalizumab or any other biologic within the last 6 months * taken or used any investigational drug or device within 30 days prior

Keywords: hidradenitis suppurativa efalizumab biologic raptiva
myopia control by combining auricular acupoint and atropine eyedrops

Conditions: Myopia

Summary: this study was designed to compare the difference of using atropine eyedrops alone from atropine combined with the stimulation of auricular acupoints therapy in reducing myopia progression.

a total of 64 school-aged children with myopia, fulfilling eligibility criteria, were recruited. they were randomly assigned to three arms: 1. 21 treated with the 0.25 % atropine each night (0.25a). 2. 20 treated with the 0.5 % atropine each night (0.5a). 3. 23 treated with 0.25 % atropine each night together with stimulation of auricular acupoints(0.25a+e). this protocol was proceeded for at least 6 months.the differences in post-treatment effects of these three groups were statistically accessed.

Eligibility criteria:
inclusion criteria: * all included patients, age from 6 to 15 years, had myopia (spherical equivalent \> -0.5 d) after cycloplegic refraction, * the astigmatism and anisometropia were less than 2.0 d, * iop was less than 21 mmhg. exclusion criteria: * the presence of related disease such as infection, ulceration, eyelid disease, ocular and auricular disorders, * individuals with amblyopia or strabismus, * individuals received any other therapies in the period of study, * individuals suffering some sort of haemostasis disorder, * individuals did not follow the treatment (eyedrops and/or stimulation of auricular acupoints) over seven days

Keywords: myopia, auricular acupoint, atropine, rct
vascular access complications for therapeutic apheresis in nephrology

Conditions: Vascular Access Complication; Apheresis Related Complication

Summary: the aim of this study is to describe vascular access complications which are used for therapeutic apheresis in nephrology.

the aim of this study is to describe vascular access complications which are used for therapeutic apheresis in nephrology. complications may include arterio-veinous fistula or graft (avf or avg) thrombosis with or without known stenosis; avf or avg or central veinous catheter (cvc) infections and cvc dysfunctions. the investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in north east france. nephrologics indications include : * acute or active antibody mediated rejection (abmr), * goodpasture disease, * anca vasculitis, * thrombotic microangiopathy (tma), * focal segmental glomerulosclerosis (fsgs), * hla or abo desensitization for kidney transplantation. data inclusion period is from june 2020 to june 2022. the aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the north east france. te investigators will study the risk factors that are associated with this complications. the second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.

Eligibility criteria:
inclusion criteria: * patients in nephrology receiveing apheresis treatment by filtration or double filtration exclusion criteria: * apheresis treatment for other indications * centrifugation apheresis treatment

Keywords: apheresis dfpp anca associated vasculitis goodpasture syndrome arterio veinous fistula arterio veinous graft
multicenter study using imc to analyze the impact of icans on microglia

Conditions: ICANS, Grade Unspecified; CAR T-Cell-Related Encephalopathy Syndrome

Summary: immunotherapy with chimeric antigen receptor (car) t cell therapy can cause immune effector cell-associated neurotoxicity syndrome (icans). however, the molecular mechanisms leading to icans are not well understood. in this study, the investigators plan to examine the role of microglia as the primary parenchymal immune cells of the central nervous system (cns) during icans in human samples. the samples will be analyzed using imaging-mass-cytometry-based analysis (imc). single-cell data will be obtained through machine learning supervised segmentation of imc data. single-cell marker expression in all cells and in microglia (iba1+ cells) will be analyzed in patients with icans.

immunotherapy with chimeric antigen receptor (car) t cell therapy can cause immune effector cell-associated neurotoxicity syndrome (icans). previous studies have shown a role for il-1beta and il-6 in xenograft mouse models. however, the molecular mechanisms leading to icans are not well understood. in this study, the investigators plan to examine the role of microglia as the primary parenchymal immune cells of the central nervous system (cns) during icans in human samples. the samples will be analyzed using imaging-mass-cytometry-based analysis (imc). single-cell data will be obtained through machine learning supervised segmentation of imc data. single-cell marker expression in all cells and in microglia (iba1+ cells) will be analyzed in patients with icans. the participants are patients treated with chimeric antigen receptor (car) t cell therapy. the patients will received tspo-pet imaging if available and if an autopsy is performed underroutine conditions tissue is collected for imc based analysis.

Eligibility criteria:
inclusion criteria: * patients that had developed icans * car t cell infusion for lymphoid malignancy (nhl or all) exclusion criteria: * lack of consent of patient or legal guardian
study of a new catheter using force sensing capabilities for the treatment of atrial fibrillation and ventricular tachycardia

Conditions: Atrial Fibrillation; Ischemic Ventricular Tachycardia

Summary: the purpose of this study is to study the treatment of atrial fibrillation and ischemic ventricular tachycardia using a rf ablation catheter with contact force sensing capabilities.


Eligibility criteria:
inclusion criteria: * symptomatic atrial fibrillation or ischemic ventricular tachycardia exclusion criteria: * longstanding persistent af * idiopathic vt * congestive heart failure

Keywords: arrhythmia electrophysiology fibrillation tachycardia ablation atrial fibrillation (af) ischemic ventricular tachycardia (vt)
evaluation of a novel medical device to facilitate gel instillation during change of long-term urinary catheters

Conditions: Urinary Catheters; Retention, Urinary; Incontinence, Urinary; Anesthesia, Local

Summary: a randomized, open label, controlled, parallel group study to investigate difference between regional standard procedure and a novel modified procedure (using an additional novel device to facilitate gel installation) for changing long-term indwelling urinary catheters.

this is a randomized, open label, controlled, parallel group study, which comprises one visit that includes: assessment for eligibility, randomization to one of two treatment alternatives, followed by the actual intervention and evaluation of outcomes. the interventions are either change of catheter according to the regional standard procedure (the comparator group) or change of catheter with the additional use of the novel device to facilitate gel instillation and a slightly modified procedure (the experimental group).

Eligibility criteria:
inclusion criteria: * the patient has an indwelling catheter and a primary diagnosis that justify continued catheter use * the patient provides informed consent prior to any study specific procedures * the patient is considered to benefit from participation in the clinical study exclusion criteria: * the patient do not consent to participate in the study * trauma to urethra or bladder * infection to urethra or bladder * other diagnosis that contraindicates participation in the clinical study as judged by the responsible physician

Keywords: urinary catheterization gel installation novel medical device indwelling urinary catheter long-term urinary catheter male patients